T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles

Nanomedicine

Volumn 8, Issue 6, 2013, Pages 891-902

  Ito, Akira ^a   Yamaguchi, Masaki ^a   Okamoto, Noriaki ^a   Sanematsu, Yuji ^a   Kawabe, Yoshinori ^a   Wakamatsu, Kazumasa ^b   Ito, Shosuke ^b   Honda, Hiroyuki ^c   Kobayashi, Takeshi ^d   Nakayama, Eiichi ^e   Tamura, Yasuaki ^f   Okura, Masae ^f   Yamashita, Toshiharu ^f   Jimbow, Kowichi ^f   Kamihira, Masamichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d CHUBU UNIVERSITY   (Japan)

^e KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

hyperthermia; magnetite nanoparticle; melanoma; T cell receptor; tumor infiltrating lymphocyte

Indexed keywords

MAGNETITE NANOPARTICLE; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL EXPANSION; COMPLEMENTARITY DETERMINING REGION; CONJUGATION; CONTROLLED STUDY; DNA SEQUENCE; HYPERTHERMIA; LYMPH NODE; MAGNETIC FIELD; MELANOGENESIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84878679602     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.142     Document Type: Article

References (44)

1. Dewhirst MW, Prosnitz L, Thrall D et al. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin. Oncol. 24(6), 616-625 (1997).
2. Van Der Zee J. Heating the patient: a promising approach? Ann. Oncol. 13(8), 1173-1184 (2002).
3. Shecterle LM, St Cyr JA. Whole body hyperthermia as a potential therapeutic option. Cancer Biother. 10(4), 253-256 (1995).
4. Storm FK, Morton DL, Kaiser LR et al. Clinical radiofrequency hyperthermia: a review. Natl Cancer Inst. Monogr. 61, 343-350 (1982).
5. Gazeau F, Lévy M, Wilhelm C. Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomedicine (Lond.) 3(6), 831-844 (2008).
6. Jordan A, Scholz R, Wust P et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int. J. Hyperthermia 13(6), 587-605 (1997).
7. Ito A, Shinkai M, Honda H et al. Medical application of functionalized magnetic nanoparticles. J. Biosci. Bioeng. 100(1), 1-11 (2005).
8. Jordan A, Wust P, Fähling H et al. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int. J. Hyperthermia. 9(1), 51-68 (1993).
9. Ito A, Kuga Y, Honda H et al. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 212(2), 167-175 (2004).
10. Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol. 29(7), 323-332 (2011).
11. Kawai N, Ito A, Nakahara Y et al. Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 66(7), 718-727 (2006).
12. Gneveckow U, Jordan A, Scholz R et al. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med. Phys. 31(6), 1444-14451 (2004).
13. Thiesen B, Jordan A. Clinical applications of magnetic nanoparticles for hyperthermia. Int. J. Hyperthermia. 24(6), 467-474 (2008).
14. Shinkai M, Le B, Honda H et al. Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J. Cancer Res. 92(10), 1138-1145 (2001).
15. Gupta AK, Naregalkar RR, Vaidya VD et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications Nanomedicine (Lond.) 2(1), 23-39 (2007).
16. Yiu HH. Engineering the multifunctional surface on magnetic nanoparticles for targeted biomedical applications: a chemical approach. Nanomedicine (Lond.) 6(8), 1429-1446 (2011).
17. Thomas PD, Kishi H, Cao H et al. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J. Invest. Dermatol. 113(6), 928-934 (1999).
18. Sato M, Yamashita T, Ohkura M et al. N-propionyl-cysteaminylphenol- magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells. J. Invest. Dermatol. 129(9), 2233-2241 (2009).
19. Johannsen M, Gneveckow U, Eckelt L et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia 21(7), 637-647 (2005).
20. Ito A, Shinkai M, Honda H et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol. Immunother. 52(2), 80-88 (2003).
21. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of 'heat-controlled necrosis' with heat shock protein expression. Cancer Immunol. Immunother. 55(3), 320-328 (2006).
22. Sato A, Tamura Y, Sato N et al. Melanoma-targeted chemo-thermo-immuno (CTI)- therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release. Cancer Sci. 101(9), 1939-1946 (2010).
23. Takada T, Yamashita T, Sato M et al. Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo- immunotherapy. J. Biomed. Biotechnol. 457936 (2009).
24. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
25. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 334(6181), 395-402 (1988).
26. Harrell MI, Iritani BM, Ruddell A. Lymph node mapping in the mouse. J. Immunol. Methods 332(1-2), 170-174 (2008).
27. Hindley JP, Ferreira C, Jones E et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 71(3), 736-746 (2011).
28. Godebu E, Summers-Torres D, Lin MM et al. Polyclonal adaptive regulatory CD4 cells that can reverse Type I diabetes become oligoclonal long-term protective memory cells. J. Immunol. 181(3), 1798-1805 (2008).
29. Böhm W, Thoma S, Leithäuser F et al. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J. Immunol. 161(2), 897-908 (1998).
30. Dyall R, Bowne WB, Weber LW et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188(9), 1553-1561 (1998).
31. Bloom MB, Perry-Lalley D, Robbins PF et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185(3), 453-459 (1997).
32. Zhai Y, Yang JC, Spiess P et al. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20(1), 15-25 (1997).
33. Rötzschke O, Falk K, Stevanovi S et al. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21(11), 2891-2894 (1991).
34. Suzuki M, Shinkai M, Honda H et al. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res. 13(2), 129-135 (2003).
35. Salameire D, Le Bris Y, Fabre B et al. Efficient characterization of the TCR repertoire in lymph nodes by flow cytometry. Cytometry A 75(9), 743-751 (2009).
36. Nitta T, Oksenberg JR, Rao NA et al. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 249(4969), 672-674 (1990).
37. Solheim JC, Alexander-Miller MA, Martinko JM et al. Biased T cell receptor usage by Ld-restricted, tum-peptide-specific cytotoxic T lymphocyte clones. J. Immunol. 150(3), 800-811 (1993).
38. Ferradini L, Roman-Roman S, Azocar J et al. Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res. 52(17), 4649-4654 (1992).
39. Shilyansky J, Nishimura MI, Yannelli JR et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Natl Acad. Sci. USA 91(7), 2829-2833 (1994).
40. Harada M, Tamada K, Abe K et al. Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 47(4), 198-204 (1998).
41. Singh V, Ji Q, Feigenbaum L et al. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J. Immunother. 32(2), 129-139 (2009).
42. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8(4), 299-308 (2008).
43. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011).
44. Jimbow K, Tamura Y, Yoneta A et al. Conjugation of magnetite nanoparticles with melanogenesis substrate, NPrCAP provides melanoma targeted, in situ peptide vaccine immunotherapy through HSP production by chemo-thermotherapy. J. Biomater. Nanobiotechnol. 3(2), 140-153 (2012).